European Hematology Association Congress | Conference

EHA 2020 Discussion Addresses New Considerations for Common Transplant Complications

June 17th 2020

A panel of hematologic experts came together for a live Q/A session to discuss promising research related to common clinical complications of hematopoietic stem cell transplantation.

Long-Term Follow-Up Confirm OS Advantage With CPX-351 in Newly Diagnosed AML

June 16th 2020

CPX-351 continued to showcase an overall survival benefit versus conventional 7+3 chemotherapy in patients with newly diagnosed high-risk/secondary acute myeloid leukemia.

Isatuximab Triplet Significantly Improves PFS in Relapsed/Refractory Myeloma

June 14th 2020

The triplet therapy of isatuximab-irfc, carfilzomib, and dexamethasone showed a statistically significant improvement in PFS versus carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Mild COVID-19 Symptoms Are Associated with Poorer Outcomes in Sickle Cell Disease

June 14th 2020

Results from a survey of patients in the United Kingdom showed patients with sickle cell disease diagnosed with COVID-19 and who had mild symptoms were more likely to die or require mechanical ventilation than those with more severe symptoms of COVID-19.

Endotheliopathy: A Marker of Progression to Critical Illness in COVID-19

June 14th 2020

Endotheliopathy represents a marker of progression to critical illness in patients with COVID-19 infection and soluble thrombomodulin segregates with mortality.

Ropeginterferon Alfa-2b Helps Maintain Hematocrit Control for Low-Risk Polycythemia Vera

June 14th 2020

More patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b were able to maintain hematocrit levels at or below 45% compared with those who received monthly phlebotomy alone.

Dr. Dimopoulos on the Safety of Zanubrutinib in Waldenström Macroglobulinemia

June 14th 2020

Meletios A. Dimopoulos, MD, discusses safety results from the randomized phase 3 ASPEN trial of zanubrutinib (Brukinsa) in patients with Waldenström macroglobulinemia.

Dr. Talati on Real-World Data With Venetoclax Combinations in AML

June 13th 2020

Chetasi Talati, MD, discusses the ongoing safety analysis of venetoclax (Venclexta)-based combinations in patients with newly diagnosed acute myeloid leukemia.

Eprenetapopt/Azacitidine Shows Encouraging Responses in High-Risk MDS/AML

June 13th 2020

The combination of eprenetapopt and azacitidine led to high objective response rates and complete response rates in patients with TP53-mutated myelodysplastic syndrome and acute myeloid leukemia.

Luspatercept-aamt Reduces RBC Transfusion Burden in Patients With Rare Blood Disorder

June 13th 2020

Data from the BELIEVE trial showed that luspatercept-aamt, a first-in-class erythroid maturation agent designed to regulate late-stage red blood cell maturation, reduced the need for red blood cell transfusions across every subgroup of patients with beta-thalassemia.